Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioxcel Therapeutics ( (BTAI) ) has provided an announcement.
BioXcel Therapeutics has restructured its credit agreement, introducing new capital-raising requirements while modifying liquidity covenants and interest rates. The company must raise specific funds by set dates and will issue new warrants as part of the agreement. Additionally, David Mack joins the board, bringing extensive legal and strategic experience, and a new patent has been listed in the FDA’s Orange Book, potentially enhancing the company’s intellectual property portfolio.
For a thorough assessment of BTAI stock, go to TipRanks’ Stock Analysis page.